Director, Health Economics & Outcomes Research (HEOR) – ARGO Franchise

About this role

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of underserved patients. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients. For more information, visit www.azurity.com.

Azurity Pharmaceuticals is proud to be an inclusive workplace and an Equal Opportunity Employer. Azurity's success is attributable to our incredibly talented, dedicated team that focuses on benefiting the lives of patients by bringing the best science and commitment to quality into everything that we do. We seek highly motivated individuals with the dedication, integrity, and creative spirit needed to thrive in our organization.

About the Role

Azurity Pharmaceuticals is a privately held specialty pharmaceutical company focused on innovative products that meet the needs of underserved patients. Within the ARGO franchise — our hospital-focused, targeted-delivery specialty business — we are building the value-evidence foundation for a portfolio of hospital and institutional products, beginning with D-PLEX100, a locally administered, extended-release surgical anti-infective for the prevention of surgical site infection.

We are seeking a Director, Health Economics & Outcomes Research (HEOR) to develop the HEOR evidence, economic models, and value dossiers that support access and reimbursement for ARGO's products in the US and Canada. Reporting to the VP, Commercial Brand Executive for ARGO, this individual owns the value-evidence strategy and deliverables for the franchise — starting with D-PLEX100 and extending to future assets — and translates clinical and economic data into the tools that hospital, payer, and health-technology-assessment decision-makers require.

Because ARGO's products are inpatient and institutionally reimbursed, this role is central to the commercial model: the HEOR Director builds the budget-impact and cost-effectiveness evidence that underpins DRG economics, the New Technology Add-On Payment (NTAP) application, hospital coding strategy, and the P&T and value-analysis-committee value story. The role partners closely with Market Access, Medical Affairs, Brand Marketing, the field organization, Regulatory, and Program Management, and manages external HEOR vendors and academic collaborators.

The ideal candidate brings a minimum of 8 years of HEOR, health economics, or value & access experience in pharmaceutical, biotech, or device, including dossier and economic-model development and US reimbursement strategy. Hospital / inpatient, anti-infective, surgical, or device experience and familiarity with both US and Canadian access environments are strongly preferred.

Key Responsibilities

Value Evidence Strategy

• Own the HEOR and value-evidence strategy for the ARGO franchise, beginning with D-PLEX100, and build the integrated evidence plan that supports US and Canadian access and reimbursement across the product lifecycle.

• Identify evidence gaps against the requirements of hospital decision-makers, payers, and health-technology-assessment (HTA) bodies, and prioritize the studies and analyses needed to close them.

• Define the economic value proposition for an inpatient, DRG-reimbursed surgical product, and align it with brand strategy and market-access objectives.

Dossiers, Models & Deliverables